SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

WORK Medical Technology Group Ltd. engages in the development of health instruments. It manufactures and sells medical devices, including endotracheal tubes, laryngeal mask airways, heat and moisture exchanging filters, disposable breathing circuits, nebulizer kits, and yankauer suction sets. The company was founded on March 1, 2022 and is headquartered in Hangzhou, China.

Work Medical Technology Group Ltd - Ordinary Shares - Class A

Work Medical Technology Group Ltd

Work Medical Technology Group is seeing intense retail speculation and volatility as traders compare its aggressive multi-day rally to past low-float Chinese pump-and-dump cycles. The community is sharply divided between those chasing the parabolic price action for massive gains and those warning of imminent bag-holding risks due to the stock's history of dilution and extreme volatility.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing intense community volatility driven by sector-wide profit-taking and geopolitical concerns, yet bulls remain highly vocal about the stock's long-term potential as an AI infrastructure leader. Traders are actively debating whether recent pullbacks represent a genuine cycle shift or a temporary buying opportunity, with significant sentiment focused on the stock's massive earnings growth and future rerating potential.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is generating significant market buzz as investors closely watch upcoming earnings for signals on infrastructure build-out progress and revenue guidance. While community sentiment is heavily polarized between long-term confidence in the company's vertically integrated AI stack and concerns over sector-wide volatility, traders are intensely focused on how the firms hyperscaler ambitions will perform against competitive peers.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is experiencing significant market interest driven by excitement over its Qwen AI platform and potential cloud monetization, fueling debate among investors over its long-term AI infrastructure value versus lingering geopolitical and e-commerce concerns. Community discussion is sharply divided, featuring both bullish sentiment from traders targeting valuation rerating and bearish warnings from skeptics focused on historical price volatility and persistent skepticism toward Chinese equities.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending after confirming the REGAL clinical trial has reached 78 of the 80 required patient events, signaling that final trial data and unblinding are imminent. The community is actively discussing the potential for a massive short squeeze given high short interest, while long-term investors are focused on the transformative potential of the GPS treatment for AML patients and the prospect of significant institutional interest or a future buyout.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is seeing significant upward momentum as investors react to a new joint development agreement with Turbine-X to provide private power infrastructure for AI-driven data centers. The community is actively debating the stock's high short interest and potential for a squeeze, weighing this bullish AI-sector catalyst against ongoing concerns regarding manufacturing scalability, dilution risks, and previous execution challenges.

Wolfspeed, Inc. is an innovator of wide bandgap semiconductors, focused on silicon carbide and gallium nitride (GaN) materials and devices for power and radiofrequency (RF) applications. Its product families include silicon carbide and GaN materials, power devices and RF devices, and its products are targeted for various applications such as electric vehicles, fast charging, 5G, renewable energy and storage, and aerospace and defense. The company was founded by Calvin H. Carter Jr., John W. Palmour, F. Neal Hunter, Eric Hunter, and John Edmond in 1987 and is headquartered in Durham, NC.

Wolfspeed Inc - Ordinary Shares (New)

Wolfspeed Inc

Wolfspeed is experiencing intense volatility and speculative interest, fueled by a mix of heavy short-interest dynamics, institutional accumulation, and ongoing debates about its post-bankruptcy share structure. The community remains sharply divided between those betting on a short squeeze or a turnaround driven by the firm's silicon carbide technology, and skeptical investors who view recent price action as an unsustainable pump linked to dilution concerns.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide is experiencing intense community focus following reports of underwhelming Q1 revenue and disappointing robotaxi performance, fueling skepticism over management's execution and the timing of recent share buybacks. Despite record year-over-year revenue growth and positive long-term partnerships with firms like Bosch and Uber, investors are expressing frustration over the stock's stagnant price action and lack of clear guidance.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is capturing investor attention as CEO Jensen Huang joins the presidential delegation to China, a move seen as a major catalyst for potential market access and deal-making. While the broader tech sector faces volatility, the community is actively discussing this strategic summit alongside high-growth expectations ahead of the upcoming earnings report.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

The iShares Semiconductor ETF (SOXX) continues to see intense speculative momentum, with investors debating whether the current parabolic rise is a sustainable AI-driven super-cycle or a classic bubble destined for a blow-off top. Community discussion is heavily divided, with bulls leveraging the AI narrative to defend aggressive buying while bears are actively scaling into inverse positions, citing extreme RSI levels and historical cycle comparisons to the dot-com era.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>AKAN is also on track for its best week ever with gains of 300% so far.</li><li>Investor sentiment across cannabis stocks improved after the U.S. Justice Department moved state-regulated marijuana toward Schedule III.</li><li>AKAN’s rally was amplified by its tiny public float of about 534,420 shares, following multiple reverse stock splits.</li></ul>Shares of Akanda Corp. (AKAN) delivered one of the biggest rallies in April among cannabis stocks, rocketing 1,700% and sharply outperforming peers as traders targeted the micro-float stock during a policy-driven sector rebound.<a href="https://stocktwits.com/symbol/AKAN">AKAN stock</a> outperformed cannabis peers, including&nbsp;<a href="https://stocktwits.com/symbol/TCNNF">Trulieve Cannabis (TCNNF)</a>, up 94%;&nbsp;<a href="https://stocktwits.com/symbol/CGC">Canopy Growth Corp. (CGC)</a>, up 30%;&nbsp;<a href="https://stocktwits.com/symbol/IGC">IGC Pharma (IGC)</a>, up 25%; and&nbsp;<a href="https://stocktwits.com/symbol/ACB">Aurora Cannabis (ACB)</a>, up 12%, over the past month. AKAN is also poised to log its best week ever,&nbsp;having more than quadrupled as of Thursday’s close.&nbsp;<img src="https://news.stocktwits-cdn.com/koyfin_20260501_083616528_png_777b15d360.webp" alt="koyfin_20260501_083616528.png"><h2 class="st-heading-2">Tiny Float, Higher Buzz For AKAN</h2>Investor sentiment for cannabis stocks got a boost after the U.S. government moved state-regulated marijuana from Schedule I toward Schedule III, pushing increased medical research access, tax treatment clarity, and regulatory legitimacy.The change revived optimism across the medical cannabis sector, with traders rotating into smaller stocks, which have exposure to future regulatory tailwinds. Akanda had previously welcomed U.S. rescheduling efforts in December, keeping the company relevant in the segment.The company operates a hemp platform focused on expanding access to medicinal-grade cannabis, CBD, and wellness products across legal markets. THC, or tetrahydrocannabinol, is the part of cannabis that produces the “high” and is therefore more tightly regulated, while CBD, or cannabidiol, does not cause intoxication and is widely used in medical and wellness treatments.&nbsp;The company implemented a 1-for-3.125 reverse stock split last year, followed by a more recent 1-for-5 reverse stock split in January. A further reverse split adjustment last month reduced its total float to 534,420 shares. Short levels for the stock currently stand at 4.7%, its highest levels in four months.&nbsp;Meanwhile, cannabis peers such as TLRY have a float of 119.28 million shares, CGC about 380.82 million, and CRON nearly 379.05 million. The comparatively tiny supply made AKAN shares more sensitive to buying pressure amid April’s cannabis rally.<h2 class="st-heading-2">Canada Cultivation Plans Take Root</h2>Akanda’s main cannabis asset is its Gabriola Island cultivation site in British Columbia, where the company currently operates under a hemp cultivation license, while working toward a full THC cultivation license covering cannabis flower and derivative products. In October, the company extended its option on the property for an additional two years.The pot firm has also been evaluating Health Canada-aligned security infrastructure requirements, including improved perimeter controls, surveillance systems, access management, and secure storage measures needed in licensing inspections for THC and CBD activities. Commercial THC production has not yet begun at the site.Akanda also exited its earlier African cultivation exposure after operations at its former unit in Lesotho ceased following an unauthorized liquidation ordered by the High Court of Lesotho in 2022, after which Akanda moved away from the region. It later discontinued operations at its Canmart distribution unit in the UK last year, citing licensing renewal costs and litigation exposure that outweighed expected near-term revenues.<h2 class="st-heading-2">Telecom Pivot Adds A Safety Net</h2>Akanda has also been gradually refocusing its strategy more heavily on Canada and Europe, while building a parallel telecommunications infrastructure platform through its unit, First Towers &amp; Fiber, in Mexico.&nbsp;As part of the pivot, the company has been expanding its dark-fiber network footprint across Central Mexico, including a recent addition of about 200 kilometers of infrastructure, which is expected to generate $2 million in contracted cash flow over 10 years. The move into telecom has added a source of contract-based income alongside Akanda’s medical cannabis business, providing investors with a potential hedge against the typical volatility in pure-cannabis companies.&nbsp;<h2 class="st-heading-2">How Do Retail Traders Feel About AKAN?</h2>On Stocktwits, retail sentiment for AKAN was ‘extremely bullish’ amid an eye-watering 231,800% surge in message volumes over the past month.<figure class="image"><img src="https://news.stocktwits-cdn.com/akan_ss_png_05e51e83c2.webp" alt="akan ss.png" width="974" height="140"><figcaption>AKAN sentiment and message volume as of April 30 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Stinkypoopypants/message/651947797">said</a>, “This is a low float that can run as high as it’s pushed. Shorts will have to cover at some point. Yes it will go down but the real question is how high can we push it?”<stembedurl>https://stocktwits.com/Stinkypoopypants/message/651947797</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/_MarginOfSanity_/message/651968893">said</a>, “Fundamentals don’t matter in a short squeeze. It’s just math. Limited supply meets infinite demand.”<stembedurl>https://stocktwits.com/_MarginOfSanity_/message/651968893</stembedurl>AKAN stock has jumped 376% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/asts-rklb-fly-lunr-stocks-rally-fcc-satellite-broadband-spectrum-rule/cZQNqL1ReIK">ASTS, RKLB, FLY, LUNR Stocks Rally As FCC Opens Door To Faster Satellite Broadband Networks</a>

AKAN stock has jumped 376% over the past year. Photo credit: Getty Images

AKAN Stock Leaves Cannabis Peers In The Smoke With A Stunning 1,700% Rally In April — What’s Fueling The Run?

The company’s primary cannabis asset remains its Gabriola Island cultivation site in British Columbia, where it operates under a hemp license.

Equity

<ul class="summary-bullets"><li>Weedcoin surged over 6% within an hour after&nbsp;a report&nbsp;that&nbsp;the Trump administration may reclassify marijuana, signaling a potential policy shift.</li><li>The move would downgrade marijuana from Schedule I, easing research restrictions without fully legalizing it at the federal level.</li><li>Despite the rally, retail sentiment&nbsp;around WEEDCOIN remained&nbsp;in&nbsp;‘bearish’&nbsp;territory, accompanied&nbsp;by ‘normal’&nbsp;levels of&nbsp;chatter on Stocktwits.</li></ul>Weedcoin (WEEDCOIN) shot up more than 6% in less than an hour on Wednesday after reports that the Trump administration is reportedly reclassifying marijuana, a sign of a possible shift in U.S. drug policy.Currently, marijuana is classified as a Schedule I drug, along with heroin and LSD. The move would reclassify marijuana to a lower classification, more in line with drugs such as ketamine and steroids, Axios&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.axios.com/2026/04/22/trump-marijuana-rule-change">reported</a>.&nbsp;Though not decriminalizing marijuana at the federal level,&nbsp;the reclassification&nbsp;would loosen restrictions on medical research and allow wider examination of its therapeutic promise.The move follows&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-moves-a-step-closer-to-reclassifying-marijuana-as-a-less-dangerous-drug-a-breakout-moment-for-weed-industry/cLICa8WREFB">an executive order</a> signed by Trump last December directing regulators to review federal marijuana laws. The administration said the move was a response to growing demand from patients seeking alternative therapies for conditions such as chronic pain, cancer, and neurological disorders.&nbsp;A drug's schedule is decided "based upon the substance's medical use, potential for abuse, and safety or dependence liability," said the DEA in a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.dea.gov/drug-information/csa%5C">statement.</a><h2 class="st-heading-2">How Retail Trades Are Reacting?</h2>The news sent markets into a frenzy, with cannabis-related assets like Weedcoin skyrocketing on investor optimism over a potential increase in research access and the long-term regulatory tailwinds for the industry.&nbsp;<a href="https://stocktwits.com/coins/weedcoin">Weekcoin’s price</a> was up over 6% in the last 24 hours,&nbsp;amid strength in the broader market with Bitcoin (BTC) crossing $78,000. On Stocktwits, retail sentiment around WEEDCOIN remained in the ‘bearish’ zone, while chatter remained at ‘normal’ levels over the past day.The sector was broadly lifted by optimism regarding potential U.S. marijuana reclassification,&nbsp;with cannabis-linked stocks and ETFs also&nbsp;moving higher&nbsp;in midday&nbsp;trade on Wednesday.Tilray (TLRY), Green Thumb (GTBIF), Trulieve (TCNNF), and Innovative Industrial Properties (IIPR) were all in the green. The ETFs rose by approximately 6% to over 20%.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/blackrock-silently-scoops-nearly-one-billion-of-bitcoin/cZBBrvuReGs">BlackRock Silently Scoops Nearly $1 Billion Of Bitcoin, Outpacing Weekly BTC Supply</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Close-up of fresh cannabis plant on sunny day. Natural pattern is on green leaf. Organic hemp is growing at farm.

Weedcoin Jumps In Minutes After Trump’s Marijuana Shake-Up Speculation Sparks Sector Frenzy

Cannabis stocks and ETFs rallied sharply, with names like TLRY, GTBIF, TCNNF, and IIPR jumping 6% to over 20% in midday trade.

Cryptocurrency

<ul class="summary-bullets"><li>Trump is seeking to move marijuana from a schedule 1 drug to a schedule 3 drug, from the levels of heroin, down to the levels of tylenol.&nbsp;</li><li>The executive order directs Trump’s administration to initiate the steps needed for the classification shift.</li></ul>Shares of Tilray Brands, Aurora Cannabis and Trulieve Cannabis pulled back on Thursday after an early rally sparked by U.S. President Donald Trump’s executive order to ease federal restrictions on marijuana lost momentum, as investors pared gains following the initial reaction to the policy move.Shares of TLRY and ACB fell 5% and 3% respectively at the time of writing while TCNNF dropped 17%.&nbsp;<h2 class="st-heading-2">Trump Pushes Medical Marijuana</h2>President Donald Trump on Thursday signed an executive order to reschedule marijuana to make it less restrictive and available for “legitimate medical uses.”Trump clarified that the order is not federal legalization and does not allow for recreational use nationwide but is instead aimed at improving medical marijuana and cannabidiol research. Trump is seeking to move marijuana from a schedule 1 drug to a schedule 3 drug, from the levels of heroin, down to the levels of tylenol.“We have people begging for me to do this, people that are in great pain for decades,” Trump said while referring to patients suffering from extreme pain and incurable diseases including cancer. The executive order directs Trump’s administration to initiate the steps needed for the classification shift.“Schedule III status will allow research studies to incorporate real-world evidence and models that can assess the health outcomes of medical marijuana and legal CBD products while focusing on long-term health effects in vulnerable populations like adolescents and young adults,” the White House said in a statement.State regulations on cannabis are currently complex. While a few U.S. states currently permit the recreational use of cannabis, some allow it for medical purposes.<h2 class="st-heading-2">How Did Trump Decide?</h2>According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-12-18/trump-signs-order-to-reclassify-marijuana-in-industry-win">report</a> from Bloomberg, Trump came to the decision following discussions with Health and Human Services Secretary Robert F. Kennedy Jr. and Centers for Medicare and Medicaid Services Administrator Mehmet Oz as well as cannabis-industry leaders including Trulieve Cannabis Corp CEO Kim Rivers. As per the report, the Centers for Medicare &amp; Medicaid Services is also expected to complete a plan to test making some Medicare patients eligible for therapies derived from cannabinoids.Jazz Pharmaceuticals’ Epidiolex is currently the only drug approved by the U.S. Food and Drug Administration composed of CBD, a psychoactive compound found in cannabis.<h2 class="st-heading-2">Tilray Plans Expansion With Trump’s Push</h2>Tilray, a producer and distributor of medical and adult-use cannabis, subsequently confirmed plans to advance its U.S. medical cannabis operations with the formation of a unit called Tilray Medical USA, Inc. The unit aims to introduce medical-grade cannabis products in targeted therapeutic formats, the company said.“This action [executive order] aligns regulation with a vast body of scientific and medical data supporting cannabis medical use and safety, economic progress, and a healthcare-focused framework, while creating a more credible foundation for medical cannabis research, clinical development, and regulatory clarity,” Tilray CEO Irwin D. Simon said.<h2 class="st-heading-2">Other Cannabis Firms Respond To Policy Change</h2>Cresco Labs applauded the executive order terming it a “cultural turning point” and a “historic shift.” Trulieve too applauded the decision while <a href="https://stocktwits.com/symbol/SMG">Scotts Miracle-Gro</a> expressed support highlighting that 39 states already legalize cannabis in some form. Scotts expects to combine its Hawthorne Gardening company subsidiary, which provides nutrients, lighting and other supplies to legal cannabis growing operations, with a cannabis company in 2026.<a href="https://stocktwits.com/symbol/HITI">High Tide</a> said that it is exploring structures that would allow it to expand its Canna Cabana retail brand into the U.S. through licensing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TLRY">TLRY</a> and <a href="https://stocktwits.com/symbol/CGC">CGC</a> trended in the ‘extremely bullish’ territory at the time of writing. Sentiment around <a href="https://stocktwits.com/symbol/MSOS">AdvisorShares Pure US Cannabis ETF</a> (MSOS), which tracks American operators, followed suit.TLRY and CGC shares are down 8% and 39% this year, respectively.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/general-motors-eyes-ex-tesla-employee-sterling-anderson-as-potential-successor-to-ceo-mary-barra-report/cLegDrmRErL">General Motors Eyes Ex-Tesla Employee Sterling Anderson As Potential Successor To CEO Mary Barra: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Cannabis plants grow in the greenhouse at Vireo Health's medical marijuana cultivation facility, August 19, 2016 in Johnstown, New York. (Photo by Drew Angerer/Getty Images)

Tilray, Aurora Cannabis, Trulieve Pull Back After Trump Marijuana Order Rally Runs Out Of Steam

Trump clarified that the order is not federal legalization and does not allow for recreational use nationwide but is instead aimed at improving medical marijuana and cannabidiol research.

Trump clarified that the order is not federal legalization and does not allow for recreational use nationwide, but is instead aimed at improving medical marijuana and cannabidiol research.


Trump Orders Federal Action to Accelerate Cannabis Research Access

President Trump directed federal agencies Thursday to complete the marijuana rescheduling process initiated under the previous administration, focusing the executive action on expanding medical research opportunities for cannabis and CBD compounds.The executive order instructs the attorney general to finalize the reclassification of marijuana from Schedule I to Schedule III under the Controlled Substances Act, a shift that administration officials characterized as removing bureaucratic obstacles to scientific study rather than addressing recreational use or criminal penalties.In a press ...

Trump Moves A Step Closer To Reclassifying Marijuana As A Less Dangerous Drug — A Breakout Moment For Weed Industry?

The cannabis industry is enjoying renewed momentum under Trump, whose administration has adopted a notably more accommodative approach toward the drug and its related products.

<ul class="summary-bullets"><li>Bloomberg reported that the Centers for Medicare &amp; Medicaid Services (CMS), which runs the Medicare program, is planning an initiative that would make some U.S. Medicare patients eligible for CBD coverage.&nbsp;</li><li>MSOS and YOLO, two key cannabis sector-focused funds, gained 3.4% and 2.7%, respectively.</li><li>The Trump administration seems to be backing cannabis as an industry, following its previous comments regarding CBD and reclassifying marijuana.</li></ul>Cannabis&nbsp;stocks advanced on Wednesday following a report speculating that certain U.S Medicare patients could soon be eligible to receive coverage for CBD under a new initiative.CBD, or cannabidiol, is a compound found in cannabis and used to treat sleep disorders, anxiety, pain, and inflammation. Some research suggests it may also treat cancer symptoms. The drug is sold as gummies, pet treats, and skincare supplements.<h2 class="st-heading-2">Cannabis Stocks Rally</h2>Tilray Brands’ shares rose 4.8%, while the over-the-counter stocks of Curaleaf Holdings, Trulieve Cannabis, and Green Thumb Industries gained between 2% to 5.6%. Shares of Innovative Industrial Properties, a real estate investment trust (REIT) that buys and leases specialized cannabis cultivation facilities, rose 1.1%.On Stocktwits, the retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/TLRY">TLRY</a> shifted to ‘extremely bullish’ from ‘bullish,’ while that for&nbsp;<a href="https://stocktwits.com/symbol/CURLF">CURLF</a> shifted to ‘bullish’ from ‘neutral.’ The sentiment was ‘bullish’ for&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">GTBIF</a>, and ‘bearish’ for&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">TCNNF</a> and&nbsp;<a href="https://stocktwits.com/symbol/IIPR">IIPR</a> as of the last reading.&nbsp;The&nbsp;<a href="https://stocktwits.com/symbol/MSOS">AdvisorShares Pure US Cannabis ETF (MSOS)</a>, which tracks U.S. cannabis companies exclusively, and the&nbsp;<a href="https://stocktwits.com/symbol/YOLO">AdvisorShares Pure Cannabis ETF (YOLO)</a>, which also tracks overseas companies and cannabis-adjacent businesses, rose 3.4% and 2.7%, respectively.<h2 class="st-heading-2">CMS Initaitive</h2>The rally came after Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-11-26/medicare-to-test-making-cbd-treatment-available-for-seniors">reported</a> that the Centers for Medicare &amp; Medicaid Services (CMS) is planning an initiative that would make some U.S. Medicare patients eligible for CBD coverage.&nbsp;Details of the proposed program aren’t available, but an early version of the plan focused on seniors in oncology and palliative care settings, according to a summary viewed by the news agency.Unnamed sources told Bloomberg that Howard Kessler, a payments financier who has advocated for expanded CBD access, met with Health and Human Services Secretary Robert F. Kennedy Jr. about the issue last month<h2 class="st-heading-2">A Trump Boost?</h2>The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. Hemp-derived cannabidiol (CBD) could "revolutionize senior healthcare" by slowing disease progression and serving as an alternative to prescription drugs, Trump had&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tilray-canopy-growth-cannabis-stocks-lose-high-premarket-after-surge-triggered-by-trumps-post/chDDTJ9R3BB">said</a> in a video post in September.The previous month, Trump said his administration was weighing a move to reclassify marijuana as a less dangerous drug under federal law.That said, doubts over cannabis efficacy in healthcare remain. A&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2836267">recent study</a> funded by the Food and Drug Administration suggested that prolonged use of CBD may cause liver toxicity, while other research suggests it can interfere with other medications, harm male reproductive health, and pose potential risks to children and pregnant women.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/holiday-shopping-could-soar-to-a-record-1-trillion-this-year-with-online-spending-blasting-to-new-highs/cL5eLqVREW6">Holiday Shopping Could Soar To A Record $1 Trillion This Year, With Online Spending Blasting To New Highs</a>

Tilray, IIPR, Trulieve, Other Cannabis Stocks Rally On Report Of Government Considering Adding CBD Treatment For Medicare Patients  

The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. 

Stocks of cannabis sellers Tilray Brands Inc. and Canopy Growth Corp.&nbsp;fell 5% and 1.3%, respectively, in the early premarket session on Tuesday.Weed stocks&nbsp;seem to be losing momentum from the previous day, when the sector rallied following President Donald Trump's post highlighting the potential benefits of using cannabidiol in senior healthcare.Hemp-derived cannabidiol (CBD) could "revolutionize senior healthcare" by slowing disease progression and serving as an alternative to prescription drugs, Trump said in a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/posts/115283887618990920">video post</a> on Truth Social on Sunday.Major companies&nbsp;<a href="https://stocktwits.com/symbol/CURLF">Curaleaf Holdings</a>,&nbsp;<a href="https://stocktwits.com/symbol/TCNNF">Trulieve Cannabis</a>, and&nbsp;<a href="https://stocktwits.com/symbol/GLASF">Glass House Brands</a> rose 37% to 21% on Monday. They have over-the-counter (OTC) shares listed in the U.S., which do not trade pre- and after-market.<a href="https://stocktwits.com/symbol/TLRY">Tilray shares</a> gained 60% hitting a 52-week high, while&nbsp;<a href="https://stocktwits.com/symbol/CGC">Canopy stock</a> ended 17% higher.On Stocktwits, the retail sentiment was 'extremely bullish' for Tilray, 'bullish' for Curaleaf, Canopy, and Trulieve, and 'bearish' for Glass House, as of early Tuesday.A bullish user projected strong gains in the stocks should a formal announcement regarding the CBD be made.<stembedurl>https://stocktwits.com/angelfromsky/message/630185575</stembedurl>Trump said last month that his administration was weighing a reclassification of marijuana. The potential move would classify marijuana as less dangerous under federal law and could lead to easing criminal penalties tied to its use.Meanwhile, regulations around the commercial use of hemp and CBD were significantly eased through the Agriculture Improvement Act, enacted during Trump's first term. As of now, marijuana remains listed as a Schedule I substance under the Controlled Substances Act, meaning it has a high potential for abuse and no current accepted medical use.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Dozens of varieties of marijuana samples are on display at a dispensary in New York. (Photo by John Paraskevas/Newsday RM via Getty Images)

Tilray, Canopy Growth: Cannabis Stocks Lose High Premarket After Surge Triggered By Trump's Post

Major weed stocks rallied the previous day after President Donald Trump's post, which highlighted the potential benefits of using cannabidiol in senior healthcare.

President Donald Trump confirmed on Monday that he is looking at reclassifying marijuana and may announce his final decision in the next few weeks. "We're looking at reclassification, and we'll make a determination over the next few weeks," Trump told reporters during a press conference about cracking down on crime in Washington, D.C.His comments come after The Wall Street Journal (WSJ)&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/politics/policy/trump-marijuana-federal-drug-classification-01a73b8c">reported</a> last week that Trump may be interested in changing the drug’s classification. Marijuana-linked stocks like Aurora Cannabis (ACB), Canopy Growth (CGC), Tilray Brands (TLRY), Cronos Group (CRON), and Trulieve Cannabis (TCNNF) were already rallying in pre-market trade on the report.&nbsp;They continued to rally after Trump’s confirmation, with&nbsp;<a href="http://stocktwits.com/symbol/CGC">Canopy Growth’s</a> stock surging nearly 30% in midday trade.&nbsp;<a href="http://stocktwits.com/symbol/TLRY">Tilray’s stock</a> jumped 22%, followed by&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="http://tcnnf">Trulieve’s stock</a> gaining more than 18%. Aurora Cannabis’s stock climbed 12.5% on Monday.On Stocktwits, retail sentiment around Canopy Growth moved higher within ‘extremely bullish’ territory amid ‘extremely high’ levels of chatter. Meanwhile, retail sentiment around Tilray Brands improved to ‘bullish’ from ‘bearish’ a day ago, and retail sentiment around Trulieve was moved higher within ‘extremely bullish’ territory.“Some people like it. Some people hate it. Some people hate the whole concept of marijuana, because if it’s bad for the children, it’s bad for people older than children,” the President said, noting that medical marijuana, specifically, may hold benefits.&nbsp;“I’ve heard great things to do with medical, and I’ve heard bad things having to do with just about everything else but medical,” he said.Reclassification of marijuana from a Schedule I drug to a Schedule III drug would ease restrictions, allow tax breaks, and expand medical research.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-declares-liberation-day-in-dc-pushes-takeover-of-city-police/chrHGOoRdee">Trump Declares ‘Liberation Day’ in DC, Pushes Takeover Of City Police</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump answers questions during a press conference in the James S. Brady Press Briefing Room of the White House August 11, 2025 in Washington, DC. (Photo by Andrew Harnik/Getty Images)

Trump Confirms Marijuana Reclassification Decision To Be Made In ‘Next Few Weeks’ 

The President noted that there’s a difference of opinion on the benefits of marijuana, but added that he’s heard “great things” with respect to medical marijuana, specifically.

Trulieve Cannabis Corp. engages in the provision of medical cannabis products and services. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Current Price	$8.10
Prev Close	$8.52
Open	$8.50
Dividend Yield	0.00%
50-Day Moving Average	$7.10
Beta	0.63
Avg. Volume	550,367.81
PE Ratio	-19.10

52-Week High	$11.83
52-Week Low	$3.25
Market Capitalization	$1.55B
EPS (Annual)	-$0.6083
Price to Book	1.33
Revenue Per Employee	$236,236.00

TCNNF
Trulieve Cannabis

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TCNNF News

TCNNFTrulieve Cannabis